|
Jan. 30, 2012 |
|
|
Dec. 17, 2018 |
|
|
jRCT2080221706 |
Phase I trial of YHI-1003 Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib |
|
Phase I trial of YHI-1003 plus Bortezomib and Dexamethasone |
Yakult Honsha Co., Ltd. |
||
TEL: +81-3-5550-8968 |
||
| 18 | ||
Interventional |
||
open-label, multicenter trial |
||
1 |
||
(1)Patients were previously diagnosed with multiple myeloma |
||
(1)Patients with uncontrolled intercurrent illness |
||
| 20age old over | ||
| No limit | ||
Both |
||
Relapsed Multiple Myeloma previously treated with Bortezomib |
||
investigational material(s) |
||
safety |
||
efficacy and pharmacokinetic profile |
||
| Yakult Honsha Co., Ltd. | |
| JapicCTI-121748 | |